AHCDC 2022 Virtual AGM Call for Abstracts! There are two categories for abstract submission: Research and Interesting Clinical Cases
Deadline for abstract submission is Friday, March 25. More details https://t.co/rPKwkspO1v
A great article in @TheSpec on advocating for better awareness of bleeding disorders in women, which just happens to be written by @PCMZhang, our board fellow and MBA student. Thank you Peter!
https://t.co/wm0T2JPavh
Mild hemophilia can be very serious and even life-threatening if injuries or bleeds are not treated promptly and adequately. The past few years, a lot of new details on this condition were published, hence the need to revisit the 2007 CHS publication.
https://t.co/i8OiTo9AYB
Summer Job Alert! Do you know someone who would love to work at camp for a week? Our Pinecrest Adventures Camp program that we host with Camp Menesetung has some great positions for you to check out & share via our LinkedIn page!
https://t.co/Rq6xucFbRJ
New #CoverArt#February2022 selected by EIC @JHMorrissey@DavidLillicrap To reestablish #blood flow in occluded vessels, tPA can be used BUT efficacy limited. Disharoon et al @NeevesLab design platform to co-deliver tPA & plasminogen based on microwheels. https://t.co/BI2kcdCENO
Call for abstracts for the AHCDC Annual General Meeting, which will be held virtually on Thursday, May 5, 2022. Submission deadline is Friday, March 25, 2022
More information here https://t.co/rPKwkspO1v
Did you miss our Hemlibra Now webinar or want to watch it again? The webinar is now available on our YouTube channel & features information as well as a call to action to help us make Hemlibra available to everyone with severe hemophilia in Canada.
https://t.co/wdpHafEtD7
Hemophilia Ontario held a Hemlibra Now! information and advocacy webinar on March 10 with Dr. David Lillicrap (starts at 19:30), patient testimonials and more information on the advocacy campaign.
Click here to access: https://t.co/nQL7hyDMZv
Heavy menstrual bleeding in women on anticoagulant treatment for venous thromboembolism: Comparison of high‐ and low‐dose rivaroxaban with aspirin. No statistically significant differences, but numerically lower with 10 vs 20 mg of rivaroxaban. https://t.co/qWqsAAFlkI
Join 3 panelists on Feb 25th, 2PM ET, to learn how the 2021 VWD Guidelines are relevant to your practice, their potential to improve diagnosis of VWD, and hear firsthand why they are important for people living with #VWD. Register: https://t.co/wUZj5AJDDO
Outstanding work @MortadaMortadah! I cannot applaud your work strongly enough! Excessive vaginal blood loss remains stigmatized, under-recognized and under-treated. This is an incredible step forward. Bravo!!! 🇸🇦 🇨🇦 @james_paulad https://t.co/jEb0tKvtle
Today is International Day of Women and Girls in Science Woman!
The day celebrates the critical role women and girls play in science and technology. AHCDC is proud to have many exceptional women as part of our community. #WomenInScience
Go and watch the great and very original video lecture by @ljpembroke on his experience as a #haemophilia B #genetherapy patient. Premiered at #EAHAD2021 and now available on his #YouTube channel!
➡️https://t.co/4RfgCEEkkn